A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Trial Profile

A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs Avelumab (Primary) ; Defactinib (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Verastem
  • Most Recent Events

    • 26 Jan 2017 According to a Verastem media release, first patient has been dosed in this study.
    • 22 Mar 2016 According to a Verastem Inc. media release, the company will present scientific data at the Society of Gynecologic Oncology 2016 Annual Meeting on Women Cancer.
    • 07 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top